Short Interest in Revolution Medicines, Inc. (NASDAQ:RVMDW) Declines By 91.3%

Revolution Medicines, Inc. (NASDAQ:RVMDWGet Free Report) was the target of a large drop in short interest during the month of January. As of January 30th, there was short interest totaling 573 shares, a drop of 91.3% from the January 15th total of 6,564 shares. Based on an average daily volume of 145,384 shares, the short-interest ratio is presently 0.0 days. Based on an average daily volume of 145,384 shares, the short-interest ratio is presently 0.0 days.

Revolution Medicines Stock Performance

NASDAQ RVMDW traded down $0.01 on Tuesday, reaching $1.55. The stock had a trading volume of 14,200 shares, compared to its average volume of 194,367. The firm has a fifty day moving average of $1.58 and a two-hundred day moving average of $0.78. Revolution Medicines has a 1-year low of $0.03 and a 1-year high of $3.59.

About Revolution Medicines

(Get Free Report)

Revolution Medicines (NASDAQ:RVMDW) is a clinical-stage oncology company focused on discovering and developing small-molecule therapies that target the RAS signaling pathway. The company’s scientific approach centers on designing molecules that selectively inhibit mutant RAS proteins and key regulators of RAS-driven cancers, with the goal of addressing tumor types that have historically been resistant to targeted therapies.

Revolution Medicines has advanced multiple pipeline candidates into clinical trials, including RMC-4630, a selective SHP2 inhibitor, and RMC-6236, an oral pan-RAS inhibitor designed to block signaling from multiple RAS mutants.

Recommended Stories

Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.